Ocuphire Pharma Investor Update

8 Nyxol's Differentiated MOA as an Alpha-1 Blocker Phentolamine Mesylate Reformulated as a Proprietary Topical Eye Drop →Nyxol™ Phentolamine Mesylate is the Active Ingredient in Nyxol: a Non-selective a1 & a2 Antagonist Blocking a1 Blocking a1 Reduces Pupil Size Dilates Blood Vessels Iris Dilator Muscle Iris Sphincter Muscle Nyxol blocks a1 receptors only found on the Iris Dilator Muscle Decreases Pupil Size (Moderate Miosis) without Affecting the Ciliary Muscle A Phentolamine mesylate is approved for 2 indications: ● Regitine® (Pheochromocytoma) - intravenous injection approved in 1952 OraVerse® (Reversal of oral anesthesia) - intramuscular injection approved in 2008 505(b)(2) Regulatory Approval Pathway Ocuphire PHARMA

View entire presentation